Shifting the Paradigm to Enable Durable and Effective Cell & Gene Therapies
NAVAN Technologies, Inc. is an enabling technology company commercializing a novel non-viral delivery platform to radically accelerate genetic engineering of human primary cells. The Nanostraw technology, exclusively licensed from Stanford University, provides direct intracellular access into hard-to-transfect primary human cells for efficient delivery of any cargo. By using a physical, non-perturbative mechanism for delivery, the challenges of viral-based cell manufacturing (time, cost and technical difficulties) are eliminated, resulting in fewer, faster operational steps.
NAVAN’s vision is to facilitate cell and gene therapies at the point of care. With the capability to streamline new therapy development and robust performance at scale, NanoStraws will greatly decrease costs, making clinical applications much more affordable and accessible.